Stock Market Update - March 13, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. BIAF - bioAffinity Technologies, Inc.
Price: $2.12 | Change: +98.13% ($1.05)
BIAF just rocketed up 98.13% in a swift move. BioAffinity Technologies, Inc. saw this significant surge primarily due to exciting developments surrounding its flagship lung cancer diagnostic, CyPath Lung.
The company announced record 2025 financial results for CyPath Lung, with revenue up 87% and the number of tests performed jumping an impressive 99%. They also forecast continued strong growth for 2026, projecting unit sales to increase by over 100%. Further boosting investor confidence, BioAffinity also initiated a large-scale 2,000-patient clinical study for CyPath Lung across 17 medical centers, supported by a significant cancer research program.
This powerful combination of a product already showing robust market adoption and a major clinical trial to further validate its effectiveness likely fueled investor enthusiasm for CyPath Lung's future potential in the medical diagnostics space.
2. AIFF - Firefly Neuroscience, Inc.
Price: $2.75 | Change: +58.05% ($1.01)
AIFF surged with a 58.05% gain, largely driven by an exciting breakthrough in its AI-powered technology. Firefly Neuroscience, Inc. announced advancements in its AI-powered EEG/ERP technology, which uses data from its FDA-cleared Evoke System. This new development suggests the technology may be able to differentiate between the three main Attention-Deficit/Hyperactivity Disorder (ADHD) subtypes. This could provide objective data to complement traditional symptom-based assessments, potentially helping clinicians with treatment and dosage decisions.
This advancement is a crucial step in Firefly's mission to establish the world's first "brain foundation model," trained on a vast repository of brain scans. It strategically positions the company to enter the substantial U.S. ADHD treatment market, estimated at over $10 billion, building on recent expansions in commercial reach and scan volumes.
3. SVCO - Silvaco Group, Inc. Common Stock
Price: $5.03 | Change: +52.42% ($1.73)
SVCO recently caught eyes with a massive 52.42% gain! This surge came after Silvaco Group, Inc. reported impressive fourth-quarter and full-year 2025 financial results on March 12, 2026, which sailed past what analysts were expecting.
The company announced a smaller Q4 loss than anticipated and beat revenue estimates, partly thanks to securing a second key artificial intelligence (AI) customer in Asia. This AI success, along with strong growth in their chip design software (TCAD) business and a record quarter for their intellectual property (IP) division, highlighted their operational strength. Silvaco also mentioned cost-cutting efforts are working better than planned.
What's particularly interesting for investors is Silvaco's clear path to profitability. The company expects to break even on operating cash flow by Q2 2026 and turn positive in Q3 2026, indicating confidence in their future performance. These combined factors – solid results today and a bright outlook for tomorrow – have clearly resonated with the market.
4. ANEB - Anebulo Pharmaceuticals, Inc.
Price: $0.55 | Change: +47.57% ($0.1773)
ANEB saw a surprising surge of +47.57% around mid-March 2026, catching many off guard. This significant gain wasn't tied to any positive news catalysts, which makes its movement particularly intriguing.
Instead, the company, Anebulo Pharmaceuticals, announced its decision in February 2026 to voluntarily delist from The Nasdaq Capital Market and deregister with the SEC, citing that the costs of being a public company outweighed the benefits. This was coupled with reported financial losses and an analyst downgrade.
The curious case of ANEB highlights how some short-term stock movements can defy conventional news drivers, potentially being influenced by technical indicators or smaller-scale trading ahead of its transition to the over-the-counter market, rather than positive fundamental developments.
5. PLYX - Polaryx Therapeutics, Inc. Common Stock
Price: $6.36 | Change: +36.77% ($1.71)
PLYX recently surged with an impressive 36.77% gain, largely driven by significant progress from Polaryx Therapeutics. The company is advancing its lead drug candidate, PLX-200, into a Phase 2 clinical trial known as SOTERIA. This trial will evaluate the drug's safety and activity across several rare pediatric lysosomal storage disorders (LSDs), including Krabbe disease. The "safe to proceed" letter from the FDA last October and the recent selection of a contract research organization (CRO) have set the stage for the trial's upcoming commencement.
Adding to the positive momentum, Polaryx has also deepened its engagement with the Krabbe disease community, highlighted by participation in key events. This commitment underscores the company's dedication not only to scientific advancement in treating rare conditions but also to fostering stronger ties with patients and caregivers. This combination of clinical trial progression and active community involvement appears to be a key factor in the stock's recent ascent.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.